CSL - Cash And Equivalent


CSL reported $2.16B in Cash and Equivalent for its fiscal semester ending in June of 2025.





Cash And Equivalent Change Date
Alterity Therapeutics Limited AUD 15.77M 9.56M Jun/2023
Arca Biopharma USD 49.52M 2.58M Mar/2026
aTyr Pharma USD 10.01M 735K Mar/2026
Bio Path 13.65M 3.37M Sep/2022
Brainstorm Cell Therapeutics USD 15K 14K Mar/2026
Cara Therapeutics USD 20.73M 684K Dec/2025
CSL USD 2.16B 633M Jun/2025
Curis USD 10.14M 10.14M Jun/2025
Immunic USD 186.63M 171.15M Mar/2026
Minerva Neurosciences USD 82.3M 70.02M Dec/2025
Sangamo BioSciences USD 38.34M 13.16M Jun/2025
TherapeuticsMD 523K 89K Jun/2024